Efficacy and cost-effectiveness analysis of 10-day versus 14-day eradication of Helicobacter pylori infection with vonoprazan amoxicillin: a prospective, multicenter, randomized controlled trial
ObjectivesTo evaluate the efficacy and cost-effectiveness of 10-day vonoprazan-amoxicillin (VA) dual therapy compared to 14-day VA therapy.MethodsA non-inferiority trial was carried out at 10 clinical centers to recruit patients with H. pylori infection. Subjects were assigned at random to either th...
Saved in:
| Main Authors: | Yunfan Dong, Zhaotao Duan, Min Liu, Yanbing Ding, Guangxia Chen, Ruifang Wang, Xiaodan Xu, Lixia Ding, Qiang Zhan, Chengyu Pan, Hui Li, Faming Yang, Xiaorong Dai, Xiangsu Li, Xudong Wu, Peng Peng, Jianrong Wang, Kewei Hu, Duanmin Hu, Qiong Jie, Zhenyu Zhang |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-03-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2025.1543352/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Efficacy and safety of vonoprazan-amoxicillin dual therapy versus bismuth-containing quadruple therapy for patients with Helicobacter pylori infection: a meta-analysis
by: Xiao Li, et al.
Published: (2025-03-01) -
Effectiveness and safety of vonoprazan and amoxicillin dual regimen with Saccharomyces boulardii supplements on eradication of Helicobacter pylori
by: Jing Yu, et al.
Published: (2024-11-01) -
Efficacy and safety of bismuth quadruple regimens containing minocycline and vonoprazan for eradication of Helicobacter pylori: Real‐world evidence
by: Qiyunna He, et al.
Published: (2024-05-01) -
Vonoprazan-based therapy versus standard regimen for Helicobacter pylori infection management in Egypt: an open-label randomized controlled trial
by: Yumna M. Shekeban, et al.
Published: (2025-05-01) -
Comparison of Amoxicillin Administered Twice versus Four Times a Day in First-Line <i>Helicobacter pylori</i> Eradication Using Tegoprazan, Clarithromycin, and Bismuth: A Propensity Score Matching Analysis
by: Jun-Hyung Cho, et al.
Published: (2024-09-01)